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ABSTRACT 
Invasive aspergdlosis remains a devastating disease, which is partly because of the inability to identitjr infected 
patients at an early stage of the disease. Recently, new diagnostic tests and procedures have been developed to 
help in identifying hgh-risk patients. High-resolution computed tomography has been shown to be a potent 
tool for detecting pulmonary abnormalities in neutropenic patients. Assays for the detection of circulating 
markers such as fungal antigens or Aspergillus DNA have been developed and show that markers can be 
detected in the blood at an early stage of infection. Also, the markers correlate with the fungal burden in the 
tissue, which allows monitoring of response to antifungal therapy. The tests and procedures that are now 
available need to be incorporated into management strategies for at-risk patients and evaluated in clinical trials. 
Although we now have markers that allow the early detection of fungal products, many questions remain 
unanswered with respect to the lunetics of the markers in different patient groups, the optimal management 
strategy and the effect of prophylaxis and treatment on the markers. Nevertheless, the implementation of new 
approaches for the management of invasive aspergdlosis offers opportunities to improve outcome of patients. 
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RATIONALE FOR DEVELOPING NEW TESTS FOR DIAGNOSING 
INVASIVE ASPERGILLOSIS 
Invasive aspergdosis is a devastating dsease, which carries a 
high morbidity and mortality. Patients at risk from infectlon 
often have compromised host defenses following cytotoxic 
therapy, organ transplantation or as a result of treatment with 
corticosteroids. Early antifungal therapy is thought to improve 
outcome but early diagnosis is often very difficult [I]. Over the 
past decades, progression with respect to the diagnosis of 
invasive aspergdlosis has been very limited. A landmark paper 
by Young et al. published in 1970 showed that the clinical 
diagnosis of invasive aspergdosis was not made in 68% of 
patients who had evidence of disease at autopsy [Z]. Another 
autopsy study in Germany showed that, over the period 1988- 
92, 68% of patients with invasive aspergdlosis had received no 
treatment [3]. The interval between the two studies was more 
than 40 years, which shows that diagnosing invasive 
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aspergdosis has remained a significant problem. In addition, 
the timely hagnosis is difficult when based on clinical signs and 
symptoms, and conventional diagnostic methods such as 
microscopy and culture. Although these methods wiU remain 
of great importance, other tests and procedures are required to 
permit early diagnosis. 
DEFINING DISEASE 
The inabihty to diagnose reliably invasive aspergdosis has led 
to the categorization of patients according to the certainty of 
the hagnosis of their fungal infection. Patients were 
considered to have proven disease if positive cultures were 
obtained from sterile sites or invasive growth of the micro- 
organism could be demonstrated in histology of a tissue sample 
obtained from the infected site. Positive cultures and abnormal 
radiographic findings were categorized as probable disease and 
persistent fever or clinical failure to a trial with antibacterial 
agents as possible fungal disease. Many different definitions are 
currently being used in various countries and institutes. A lack 
of standardization of definitions hampers the interpretation and 
comparison of diagnostics and efficacy of antifungal agents. A 
recent review of 173 c h c a l  studies that included 367 test 
patients showed that the agreement between definitions and 
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nomenclature withm different stuhes was very low [4]. 
Consensus definitions for invasive fungal infections have now 
been established for patients with cancer and are discussed in 
more detail elsewhere in this issue. 
LIMITATIONS OF THE CONVENTIONAL MANAGEMENT 
STRATEGY OF INVASIVE ASPERGILLOSIS 
An ideal test for diagnosing invasive aspergdlosis should have 
good performance characteristics, give a high level of certainty 
with respect to the presence or absence of disease, and should 
become positive at an early stage of infection. A single test that 
incorporates these features is currently not available, and 
combining information from different tests and procedures is 
required. The conventional approaches to managmg invasive 
aspergillosis have in common that they have relied on markers 
of disease with poor performance characteristics and which 
become positive at advanced stages of dsease. This has led to 
the clinical practice of adrmnistering antifungal agents 
empirically to those patients with a hgh suspicion of invasive 
aspergillosis, even when the presence of infection could not be 
documented. The main problem is that, in many cases, the 
diagnostic work-up for invasive aspergillosis is commenced 
after patients present with fever that persists during antibacter- 
ial therapy or develop pulmonary infiltrates on the chest X-ray 
during antibacterial treatment. Fever is used as a marker for 
disease but is a sign with verj low specificity. The chest X-ray 
is known to have a low sensitivity in this patient group due 
to neutropenia. 
Proof of invasive infection by Aspergillus species can only be 
obtained by showing invasive growth in tissue and culturing 
the fungus from the same specimen. As cited previously, in 
many patients, proofis obtained only at autopsy. Ante mortem 
invasive procedures are used in non-neutropenic patients, but 
they are often not considered in patients who receive therapy 
for hematological malignancy resulting from severe thrombo- 
cytopenia. However, a recent study showed that, in this 
patient group, radiologically guided, fine-needle biopsies had a 
high diagnostic yield and could be performed without 
complications [5] .  Unfortunately, in several cases, a false- 
negative result was obtained, whch indicated that therapeutic 
decisions could not be made solely on the basis of the biopsy 
result [ 5 ] .  
Culture is regarded as a useful tool to diagnose invasive 
aspergdlosis but the positive predictive value depends on the 
prevalence of disease and on the patient group. The optimal 
specimen for pulmonary aspergillosis appears to be bronch- 
oalveolar lavage (BAL), and culture of BAL contributes to the 
diagnosis in 30-50% of patients [6,7]. However, the decision 
to perform bronchoscopy is made afier pulmonary infiltrates 
are detected by radiodiagnostic techniques in patients with 
persistent fever, w h c h  may cause delay of diagnosis. In 
admuon, both culture and especially histology require some 
time before results become available. 
ALTERNATIVE APPROACHES TO DIAGNOSING INVASIVE 
ASPERGILLOSIS 
The Qfficulnes in managmg pahents with invasive aspergdlosis 
have lead to the development of alternative tests and 
procedures that enable early detectlon of dlsease. Among the 
most promsing are lugh resoluQon computed tomography 
(CT-scan) of the chest and nonculture-based mcrobiologcal 
methods. The latter procedure includes the detection of 
circulatmg Aspergrllus DNA and anhgens produced by the 
fungus. Because both techruques detect circulatmg markers 
of dlsease, they are especially useful m patlents mth 
thrombocytopenia. 
High-resolution CT scans 
Neutropenic pahents are prone to a vanety of pulmonary 
comphcahons and hgh-resoluhon C T  is an excellent way to 
detect pulmonary a b n o h h e s .  However, the finQngs are 
generally nonspecific and their usefulness depends on the 
spectrum of pathogens that causes pulmonary Qsease Clearly, 
this wll vary between mfferent levels of immunosuppression 
and the underlymg dsease of the pahent. CT scans of the chest 
are more senslhve than plain chest X-rays in detechng 
abnormahties in neutroperuc patlents. Severd charactenshc 
lesions have been descnbed that are h~ghly suggesnve of fungal 
infectlon. In neutropemc pauents, fungal infection often 
appears as a nodule surrounded by a halo of ground-glass 
attentuatlon (halo-sign) [8]. The halo sign is apparent in early 
stages of infechon ody and, later on, nonspecific lesions may 
predommate Typical cavlnes may occur in later stages of 
ifechon, often after recovery of the aplasia. 
CT scanning has proved to be a very useful tool when used 
very early and systematlcally in febnle neutropenia. Sumval of 
patlents was shown to improve when systematic CT scanmng 
was combined wth an aggressive approach of prompt 
anufungal treatment and surgery as compared wth the more 
convenhond approach of  using CT scanning in pahents m t h  
fever refractory to antlbactenal therapy [9]. Of course the 
a v d a b d q  of CT s c m n g  may be hmted in many centers 
and patlents have to leave their protected envlronment to 
undergo imagmg. 
PCR 
Numerous protocols for the detection of fbngal DNA in 
human specimens have been established [lo-141. Although 
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early protocols focused on the detection of DNA of single 
species or genera [10,11], more recent protocols use universal 
fungal PCR primers, which enables the detection of a broad 
range of fung, including both yeasts and molds [12-141. 
Identification of the pathogen could take place by hybridiza- 
tion of the amplification product with specific oligonucleotide 
probes [13]. Using these protocols a sensitivity of 1-10 fg of 
fungal DNA can be achieved. In one study, the sensitivity of 
the P C R  with whole blood was 100% in patients with 
documented invasive fungal infection when two or more 
samples were analyzed [13]. Positive P C R  results in whole 
blood preceded clinical signs and symptoms by a meman of 2 
days and clinical magnosis by a median of 9 days [15]. In 
addition to detection of invasive hngal infections, PCR can 
be used for monitoring the response to antifungal therapy. In 
patients with invasive aspergdlosis, the number of positive 
PCR samples declined in those who responded to treatment as 
opposed to patients who failed therapy [13]. Quantitative 
P C R  will help to monitor the fungal burden in relation to 
response to treatment, as has been shown for P C R  monitoring 
of CMV disease [16]. 
Technical advances, such as Taqman and lightcycler 
techniques, combine amplification, probe hybridization and 
signal generation, allowing the determination of the quantity 
of fungal DNA in the specimen. Although many investigators 
have reported very good performance characteristics of 
their in-house PCR assay, comparison between different 
assays is virtually impossible unless head-to-head comparisons 
are made. Lack of standarhzation remains a significant 
drawback of PCR-based methods and limits its broad use in 
clinical practice. 
The in-house PCR assays make use of different samples, 
such as serum vs. plasma vs. whole blood, mfferent protocols 
for sample preparation, and dfferent fungal DNA targets. Each 
step needs to be optimized and the fine details appear to 
have significant impact on recovery of DNA or performance 
of the assay. For instance, when plasma PCR was compared 
with whole blood PCR, the detection limit of both assays 
was equivalent when spiked samples were analyzed, but 
the sensitivity of plasma PCR was lower than that of P C R  
on whole blood when patient samples were analyzed [17]. 
The variability in PCR protocols is, in part, the consequence 
of a lack of understanding of the kinetics of fungal DNA 
in infected patients. At present, it is unknown how the 
fungal DNA is released &om the site of infection and in which 
form it circulates in the blood. Aspergillus DNA could be 
present within fragments of hyphae that are released at the 
site of infection and then circulate in the blood. Alternatively, 
the DNA could be associated with circulating cells such 
as erythrocytes or neutrophils, or could circulate as naked 
DNA. Unless we understand the mechanisms of release and 
clearance of the Aspergillus DNA, it will not be possible 
to establish an optimal protocol for DNA isolation and 
detection. Finally, molds are ubiquitous in the environment 
and the risk of contamination of PCR buffers, by airborne 
spores or by carry-over is high unless controlled by specific 
measures [10,18]. 
Detection of galactomannan 
The detection of AspergilZus antigen appears ‘to be a useful tool 
for the early diagnosis of invasive aspergdlosis in patients with 
hematological malignancy. The antigen is released by 
Aspergillus species that grow in the tissue and can be detected 
in body fluids including serum, urine, bronchoalveolar lavage 
fluid, pericardial fluid and cerebrospinal fluid [19-211. Most 
experience has been obtained with a commercial sandwich 
enzyme-linked immunosorbent assay @LISA, Platelia Asper- 
gdlus, Bio-Rad, Naraes-La-Coquette, France) that detects 
galactomannan. The detection limit of the sandwich elisa in 
serum was 0.5-1 .O ng of galactomannan per mL. The Platelia 
Aspergdlus has a sensitivity of 50-90% and a specificity of 81- 
93% [22]. In a prospective, pathology-controlled study a 
sensitivity and specificity of 92.6% and 95.4%, respectively, 
were reported when serial monitoring was performed [23]. 
Furthermore, galactomannan could be detected in the serum 
at an early stage of infection, often before clinical signs and 
symptoms or ra&ological a b n o d t i e s  suggestive of invasive 
aspergdlosis became apparent [24,25]. There is also some 
evidence that the course of the antigen titer corresponds with 
the clinical outcome of disease [24,26,27]. However, both 
fdse positive- and false-negative reactivity have been reported. 
ELISA reactivity in patients without invasive aspergllosis 
could be caused by absorption of galactomannan from the 
intestine due to cytotoxic therapy induced mucosal barrier 
injury [28]. False-negative reactivity has been observed in 8- 
10% of patients with documented disease [23]. The cause of 
false-negative reactivity is unknown, but could be the result of 
several factors, including variable ability of Aspergillus strains to 
produce and release galactomannan, or host factors, such as the 
production of high levels of antigalactomannan antibody that 
might interfere with the assay. The level of angioinvasion 
could also be a key factor in the release of antigen &om the site 
of infection. 
The Platelia Aspergillus detects galactomannan that is 
released by Aspergillus and Penicillium species, but infections 
caused by other moulds such as Fusarium or Zygomycetes are 
not detected. Furthermore, the assay has been reported to give 
a high number of positive results in neonates without invasive 
aspergdlosis [29] and false negative reactivity was reported in a 
patient with chronic granulomatous dsease [30]. 
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Detection of glucan 
Recently, a method has become available that can determine 
the concentration of (1 -t3)-P-~-glucan with high sensitivity 
and specificity. (13)-P-D-Glucan is a characteristic cell-wall 
component of fungi, except for Zygomycetes and, to a lesser 
extent, for cryptococci [31]. Prokaryotes and viruses lack this 
polysaccharide as well as the cells of humans. Therefore, it will 
make a good indicator of systemic fungal infection, if 
detectable in blood or other normally sterile body fluids. 
The method depends on the activation by t h s  glucan of Factor 
G, a horseshoe-crab coagulation factor that is extremely 
sensitive to the polysaccharide. A broad range of fun@ induces 
reactivity, including the most common pathogens Candida and 
Aspergillus. A sensitivity of 90% and a specificity of 100% were 
reported in a study of over 200 febrile episodes in patients who 
underwent treatment for hematological malignancy [30]. Most 
experience has been obtained in Japan and results of further 
evaluation in other countries are awaited. 
Although nonculture-based diagnostic methods are poten- 
tially powerful techniques, up to now, there has been no study 
that shows that the use of these methods has any significant 
impact on patient management or survival. Only one study 
showed that the systematic use of high-resolution C T  scanning 
improved the survival of patients [9]. A systematic manage- 
ment approach to high-risk patients, which incorporates 
several of the tests and procedures mentioned here may 
improve patient outcome or at least reduce the number of 
patients that receive unnecessary antifungal therapy. 
STRATEGIES FOR MANAGEMENT OF INVASIVE 
ASPERGILLOSIS 
Once tests or procedures have been shown to perform well in 
routine day-to-day clinical practice, they need to be 
incorporated into the current diagnostic work-up for invasive 
aspergdlosis, by designing management strategies. Because 
invasive aspergdlosis is a life-threatening disease, an aggressive 
approach of risk patients is required, aimed at identifjing 
patients as early as possible and initiating antifungal therapy 
promptly. Computer models such as decision analysis can aid 
in determining the feasibility of management strategies, as has 
been performed for patients with hematologd malignancies 
[32]. Then, the magnostic strategy as a whole needs to be 
evaluated by comparing the new approach with the conven- 
tional approach in clinical trials in order to determine if the 
new approach improves patient selection and preferably 
patient outcome. 
With respect to nonculture-based diagnostic methods for 
invasive fungal infections, it appears that the maximal benefit 
can be obtained when patients are sampled regularly, i.e. at 
least twice a week, samples are analyzed prospectively during 
the period of high risk and, when sampling is continued, 
during antifungal therapy. 
One possible approach would be to screen high-risk patients 
for the presence of markers during the period of highest risk. 
Once circulating markers are detected and confirmed, a 
diagnostic work-up is performed. This could include a CT 
scan of the chest and bronchoscopy. If the presence of disease is 
conhned,  then antihngal treatment is started and monitoring 
of the circulating marker is continued. In this circumstance, the 
nonculture-based assays are not used as &agnostic tools but as 
screening tools, i.e. to select patients that are at very high risk of 
developing disease. A decision analysis of a conventional 
strategy based on clinical diagnosis and chest X-rays compared 
with an alternative strategy that combined screening for 
circulating antigen with CT scanning showed that the number 
of patients that required therapy was significantly reduced when 
the alternative strategy was followed 1321. In this pre-emptive 
treatment strategy, the limited number of patients that require 
treatment could be treated with less toxic but more expensive 
antifungal agents as primary therapy. 
However, the selection of high-risk patients that require 
systematic screening is essential. When an assay is used as a 
screening test, the incidence of disease becomes a very 
important factor, especially when the incidence of disease is 
very low. The incidence of disease greatly influences the 
positive predictive value (PPV) and negative predictive value 
(NPV) of the assay. In Table 1, the PPVs and NPVs were 
calculated for several incidences of invasive aspergdlosis and 
using the test characteristics for antigen detection by Platelia 
Aspergus and whole blood PCR [15,23]. When the 
incidence of infection is 0.5%, as is the case in kidney 
transplant recipients [33], only one out of 10 patients with a 
positive antigen test and one of 70 with a positive P C R  result 
will actually have invasive aspergdlosis. Antigen detection 
appears to have a better PPV at low incidence of &sease 
compared with whole blood PCR. However, each assay has 
its drawbacks, with antigen detectioii having false-negative 
results and whole blood PCR false-positive results. The 
Table 1 Positive (PPV) and negative predictive value (NPV) of 
Aspergillus antigen detection by Platelia Aspergillus and whole blood 
PCR for different incidences of invasive aspergillosis 
Incidence of Antigen detection Whole blood PCR 
invasive 
aspergillosis ( O h )  PPV (%) NPV (%) PPV (%) NPV (%) 
~ 
0.5 10 95.4 1.4 100 
5 50 95.7 13 100 
10 69 96.6 24 100 
20 84 97.5 82 100 
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advantage of PCR is that a negative result always correlated 
with absence of disease. In optimizing a management strategy, 
these advantages and drawbacks need to be weighed and 
different approaches may emerge for different risk populations. 
Over recent years, progress has been made in the 
development and evaluation of diagnostic tests and procedures 
for diagnosing invasive infections by Aspergillus species. One 
of the most important of these is the use of high-resolution 
CT scanning of the chest. The use of circulating markers 
will significantly contribute to our management of high- 
risk patients, although many questions still remain unan- 
swered. Knowledge concerning the kinetics of the markers in 
vivo, the relation between the site of infection and release of 
markers, the performance of the assays in dlfferent patient 
groups and the effect of chemoprophylaxis on release of the 
markers are some areas that need to be explored - especially 
when we increasingly rely on these assays for prospective 
screening and make clinical decisions based on test results. 
The broad use of these assays will help us to understand hrther 
the pathogenesis of invasive aspergdlosis and ultimately 
improve outcome. 
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